Search results
Results from the WOW.Com Content Network
Turbo cancer is an anti-vaccination conspiracy theory [1] alleging that people vaccinated against COVID-19, especially with mRNA vaccines, are suffering from a high incidence of fast-developing cancers.
A study conducted on 44 rats injected with the Pfizer–BioNTech COVID-19 vaccine at doses over 300 times the human dose by body weight and 44 rats injected with placebo found no statistically significant evidence of any adverse effects on the fertility of female rats or on the health of the offspring of rats (the 3% lower pregnancy rate found ...
The specific use of the term "vaccine shedding" has risen to public prominence through anti-vaccine activists linked to misinformation related to COVID-19, who erroneously claim that COVID-19 vaccination can cause individuals to shed coronavirus spike protein and affect menstruation and fertility in women exposed to them.
The findings in the new report come from the analysis of nearly 1,300 death certificates of Oregon residents ages 16 to 30 who died from any heart condition or unknown reasons between June 1, 2021 ...
During the COVID-19 pandemic, anti-vaccination misinformation about COVID-19 circulated on social media platforms related to the spike protein's role in COVID-19 vaccines. Spike proteins were said to be dangerously "cytotoxic" and mRNA vaccines containing them therefore in themselves dangerous. Spike proteins are not cytotoxic or dangerous.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
The vaccine consists of a version of the receptor binding domain (RBD) of the SARS‑CoV‑2 spike protein, together with the adjuvants aluminium hydroxide gel and CpG 1018. [2] As the RBD protein is poorly immunogenic alone, adjuvantation is essential for a RBD-based vaccine immunogenicity. [ 9 ]
A number of COVID‑19 vaccines began to become approved and available at scale in December 2020, with vaccinations beginning to ramp up at scale from the beginning of 2021, among them the Oxford–AstraZeneca COVID‑19 vaccine, based on an adenovirus vector and internally termed AZD1222. [citation needed]